Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136807 · ClinicalTrials.gov registry record
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
A clinical trial of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT05136807 is a study of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 400 participants, below the 644-participant average among 11 other Monoclonal Gammopathy of Undetermined Significance trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05136807, a study of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2016-06-07 |
| Est. Completion | 2027-02-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05136807
The ClinicalTrials.gov registry entry for NCT05136807 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 644-participant average among 11 other Monoclonal Gammopathy of Undetermined Significance trials with a reported enrollment target (38% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Monoclonal Gammopathy of Undetermined Significance appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05136807 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05136807 about?
NCT05136807 is a clinical study titled "Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies". This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of ...
What is the current status of trial NCT05136807?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2016-06-07. Estimated completion is 2027-02-02.
What conditions does trial NCT05136807 study?
This clinical trial studies the following conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT05136807?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT05136807?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05136807 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Monoclonal Gammopathy of Undetermined Significance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Sleep Apnea in Patients With MGUS and MM
RECRUITING
-
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
RECRUITING
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
RECRUITING · Phase 2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
RECRUITING · NA
Explore more on PlainTrial
Monoclonal Gammopathy of Undetermined Significance
All registered trials for this condition
Smoldering Plasma Cell Myeloma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.